221 related articles for article (PubMed ID: 35579819)
41. Inferring ADR causality by predicting the Naranjo Score from Clinical Notes.
Rawat BPS; Jagannatha A; Liu F; Yu H
AMIA Annu Symp Proc; 2020; 2020():1041-1049. PubMed ID: 33936480
[TBL] [Abstract][Full Text] [Related]
42. Validation and Reproducibility of the Updated French Causality Assessment Method: an Evaluation by Pharmacovigilance Centres & Pharmaceutical Companies.
Théophile H; Dutertre JP; Gérardin M; Valnet-Rabier MB; Bidault I; Guy C; Haramburu F; Hillaire-Buys D; Méglio C; Arimone Y
Therapie; 2015; 70(5):465-76. PubMed ID: 26423144
[TBL] [Abstract][Full Text] [Related]
43. A tailor-made approach for causality assessment for ADR reports on drugs and vaccines.
Oosterhuis I; Zweers P; Rümke H; Muller-Hansma A; van Puijenbroek EP
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):544-550. PubMed ID: 30168222
[TBL] [Abstract][Full Text] [Related]
44. Consensus clustering for case series identification and adverse event profiles in pharmacovigilance.
Norén GN; Meldau EL; Chandler RE
Artif Intell Med; 2021 Dec; 122():102199. PubMed ID: 34823833
[TBL] [Abstract][Full Text] [Related]
45. An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme.
Masuka JT; Khoza S
Pharmacol Res Perspect; 2020 Oct; 8(5):e00657. PubMed ID: 32930524
[TBL] [Abstract][Full Text] [Related]
46. Rates of spontaneous reports of adverse drug reactions for drugs reported in children: a cross-sectional study with data from the Swedish adverse drug reaction database and the Swedish Prescribed Drug Register.
Wallerstedt SM; Brunlöf G; Sundström A
Drug Saf; 2011 Aug; 34(8):669-82. PubMed ID: 21751827
[TBL] [Abstract][Full Text] [Related]
47. Implementation and comparison of two text mining methods with a standard pharmacovigilance method for signal detection of medication errors.
Eskildsen NK; Eriksson R; Christensen SB; Aghassipour TS; Bygsø MJ; Brunak S; Hansen SL
BMC Med Inform Decis Mak; 2020 May; 20(1):94. PubMed ID: 32448248
[TBL] [Abstract][Full Text] [Related]
48. Identifying Drug-Drug Interactions in Spontaneous Reports Utilizing Signal Detection and Biological Plausibility Aspects.
Kontsioti E; Maskell S; Anderson I; Pirmohamed M
Clin Pharmacol Ther; 2024 Jul; 116(1):165-176. PubMed ID: 38590106
[TBL] [Abstract][Full Text] [Related]
49. Application of Augmented Intelligence for Pharmacovigilance Case Seriousness Determination.
Routray R; Tetarenko N; Abu-Assal C; Mockute R; Assuncao B; Chen H; Bao S; Danysz K; Desai S; Cicirello S; Willis V; Alford SH; Krishnamurthy V; Mingle E
Drug Saf; 2020 Jan; 43(1):57-66. PubMed ID: 31605285
[TBL] [Abstract][Full Text] [Related]
50. Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®.
Ampadu HH; Hoekman J; de Bruin ML; Pal SN; Olsson S; Sartori D; Leufkens HG; Dodoo AN
Drug Saf; 2016 Apr; 39(4):335-45. PubMed ID: 26754924
[TBL] [Abstract][Full Text] [Related]
51. Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase.
Sandberg L; Taavola H; Aoki Y; Chandler R; Norén GN
Drug Saf; 2020 Oct; 43(10):999-1009. PubMed ID: 32564242
[TBL] [Abstract][Full Text] [Related]
52. Comparison of the Liverpool Causality Assessment Tool vs. the Naranjo Scale for predicting the likelihood of an adverse drug reaction: A retrospective cohort study.
Um SH; Abuzgaia A; Rieder M
Br J Clin Pharmacol; 2023 Aug; 89(8):2407-2412. PubMed ID: 36849649
[TBL] [Abstract][Full Text] [Related]
53. Development of an automated assessment tool for MedWatch reports in the FDA adverse event reporting system.
Han L; Ball R; Pamer CA; Altman RB; Proestel S
J Am Med Inform Assoc; 2017 Sep; 24(5):913-920. PubMed ID: 28371826
[TBL] [Abstract][Full Text] [Related]
54. Artificial Intelligence for Unstructured Healthcare Data: Application to Coding of Patient Reporting of Adverse Drug Reactions.
Létinier L; Jouganous J; Benkebil M; Bel-Létoile A; Goehrs C; Singier A; Rouby F; Lacroix C; Miremont G; Micallef J; Salvo F; Pariente A
Clin Pharmacol Ther; 2021 Aug; 110(2):392-400. PubMed ID: 33866552
[TBL] [Abstract][Full Text] [Related]
55. Application of machine learning models to animal health pharmacovigilance: A proof-of-concept study.
Whittle E; Novotny MJ; McCaul SP; Moeller F; Junk M; Giraldo C; O'Gorman M; de Chenu C; Dzavan P
J Vet Pharmacol Ther; 2023 Nov; 46(6):393-400. PubMed ID: 37212429
[TBL] [Abstract][Full Text] [Related]
56. "Artificial Intelligence" for Pharmacovigilance: Ready for Prime Time?
Ball R; Dal Pan G
Drug Saf; 2022 May; 45(5):429-438. PubMed ID: 35579808
[TBL] [Abstract][Full Text] [Related]
57. A Feasibility Study of Drug-Drug Interaction Signal Detection in Regular Pharmacovigilance.
Hult S; Sartori D; Bergvall T; Hedfors Vidlin S; Grundmark B; Ellenius J; Norén GN
Drug Saf; 2020 Aug; 43(8):775-785. PubMed ID: 32681439
[TBL] [Abstract][Full Text] [Related]
58. Adverse drug reactions: physicians' opinions versus a causality assessment method.
Miremont G; Haramburu F; Bégaud B; Péré JC; Dangoumau J
Eur J Clin Pharmacol; 1994; 46(4):285-9. PubMed ID: 7957509
[TBL] [Abstract][Full Text] [Related]
59. Complementing Observational Signals with Literature-Derived Distributed Representations for Post-Marketing Drug Surveillance.
Mower J; Cohen T; Subramanian D
Drug Saf; 2020 Jan; 43(1):67-77. PubMed ID: 31646442
[TBL] [Abstract][Full Text] [Related]
60. The Social Impact of Suspected Adverse Drug Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database.
Castillon G; Salvo F; Moride Y
Drug Saf; 2019 Jan; 42(1):27-34. PubMed ID: 30121742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
